Valuation: Talphera, Inc.

Market Cap 4.7Cr 4.26Cr 3.94Cr 3.56Cr 6.7Cr 443.41Cr 6.94Cr 47Cr 19Cr 236.86Cr 18Cr 17Cr 751.86Cr P/E 2026 *
-4.18x
P/E 2027 * -4.17x
Enterprise Value 4.7Cr 4.26Cr 3.94Cr 3.56Cr 6.7Cr 443.41Cr 6.94Cr 47Cr 19Cr 236.86Cr 18Cr 17Cr 751.86Cr EV / Sales 2026 *
-
EV / Sales 2027 * 105x
Free-Float
78.51%
Yield 2026 *
-
Yield 2027 * -
1 day-12.46%
1 week-13.71%
Current month-12.04%
1 month-14.53%
3 months-26.34%
6 months+0.95%
Current year-20.53%
1 week 0.77
Extreme 0.77
1.17
1 month 0.77
Extreme 0.77
1.17
Current year 0.69
Extreme 0.6866
1.5
1 year 0.69
Extreme 0.6866
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
15.26
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 06/03/2017
Director of Finance/CFO 56 01/08/2017
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 60 01/08/2006
Director/Board Member 72 01/02/2010
Chairman 75 11/02/2013
Date Insider Type Main position Quantity % Market Cap. Importance
20/05/26 Tax

Chief Technology Officer

-4,518 0.0090%
02/04/26 Tax

Chief Executive Officer

9,938 0.0199%
02/04/26 Tax

Chief Technology Officer

2,444 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-12.46%-13.71%-27.52%+95.26% 4.7Cr
+1.26%+6.61%+40.79%+136.32% 1,28600Cr
+0.79%+3.45%+45.84%+93.52% 69TCr
+0.20%+1.28%+26.97%+113.70% 52TCr
-0.44%+3.69%+41.45%+68.91% 39TCr
+0.55%+0.70%+59.02%+44.62% 36TCr
-0.12%+0.74%+28.39%+58.54% 30TCr
+0.37%+0.37%+3.33%+37.27% 29TCr
-0.30%+1.14%+38.29%+72.46% 25TCr
+0.08%+0.71%+34.44%+124.95% 21TCr
Average -1.01%+0.50%+29.10%+84.55% 43TCr
Weighted average by Cap. +0.54%+3.26%+37.70%+96.50%

Financials

2026 *2027 *
Net sales - 4L 4L 4L 3L 6L 4.21Cr 7L 45.01L 17.85L 2.25Cr 16.77L 16.42L 7.15Cr
Net income -1.56Cr -1.41Cr -1.31Cr -1.18Cr -2.22Cr -147.17Cr -2.3Cr -16Cr -6.23Cr -79Cr -5.86Cr -5.73Cr -249.55Cr -1.86Cr -1.69Cr -1.56Cr -1.41Cr -2.66Cr -175.7Cr -2.75Cr -19Cr -7.44Cr -94Cr -6.99Cr -6.84Cr -297.92Cr
Net Debt - -
Projected Income Statement - Annual - Talphera, Inc.
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
13/26/13 $0.9060 -12.46% 12,20,316
12/26/12 $1.035 -1.43% 94,844
11/26/11 $1.050 0.00% 1,86,256
10/26/10 $1.050 -3.67% 1,35,575
09/26/09 $1.090 +3.81% 3,68,778
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Talphera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9060USD
Average target price
3.125USD
Spread / Average Target
+244.92%
  1. Stock Market
  2. Stocks
  3. TLPH Stock